221 related items for PubMed ID: 17270002
1. Efficacy of tegaserod for functional constipation in Chinese subjects: a randomized double-blind controlled trial in a single centre.
On Chan AO, Mo Hui W, Leung G, Hu WH, Lam SK, Wong BC.
Aliment Pharmacol Ther; 2007 Feb 15; 25(4):463-9. PubMed ID: 17270002
[Abstract] [Full Text] [Related]
2. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
Kamm MA, Müller-Lissner S, Talley NJ, Tack J, Boeckxstaens G, Minushkin ON, Kalinin A, Dzieniszewski J, Haeck P, Fordham F, Hugot-Cournez S, Nault B.
Am J Gastroenterol; 2005 Feb 15; 100(2):362-72. PubMed ID: 15667494
[Abstract] [Full Text] [Related]
3. Review article: tegaserod for chronic constipation.
Johanson JF.
Aliment Pharmacol Ther; 2004 Nov 15; 20 Suppl 7():20-4. PubMed ID: 15521851
[Abstract] [Full Text] [Related]
4. Efficacy of tegaserod in chronic constipation in men.
Fried M, Johanson JF, Gwee KA, Wagner A, Pecher E, Rueegg P.
Am J Gastroenterol; 2007 Feb 15; 102(2):362-70. PubMed ID: 17156137
[Abstract] [Full Text] [Related]
5. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA.
Am J Gastroenterol; 2008 May 15; 103(5):1217-25. PubMed ID: 18477346
[Abstract] [Full Text] [Related]
6. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
Tegaserod Clinical Research Group.
Zhonghua Nei Ke Za Zhi; 2003 Feb 15; 42(2):88-90. PubMed ID: 12783702
[Abstract] [Full Text] [Related]
7. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
Reilly MC, Barghout V, McBurney CR, Niecko TE.
Aliment Pharmacol Ther; 2005 Sep 01; 22(5):373-80. PubMed ID: 16128674
[Abstract] [Full Text] [Related]
8. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation.
Müller-Lissner S, Kamm MA, Musoglu A, Earnest DL, Dunger-Baldauf C, Shetzline MA.
Am J Gastroenterol; 2006 Nov 01; 101(11):2558-69; quiz 2671. PubMed ID: 17090282
[Abstract] [Full Text] [Related]
9. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.
Bardhan KD, Forbes A, Marsden CL, Mason T, Short G.
Aliment Pharmacol Ther; 2004 Jul 15; 20(2):213-22. PubMed ID: 15233702
[Abstract] [Full Text] [Related]
10. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation.
Di Palma JA, Cleveland MV, McGowan J, Herrera JL.
Am J Gastroenterol; 2007 Sep 15; 102(9):1964-71. PubMed ID: 17573794
[Abstract] [Full Text] [Related]
11. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.
Aliment Pharmacol Ther; 2005 Feb 15; 21(4):435-44. PubMed ID: 15709995
[Abstract] [Full Text] [Related]
12. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
Tack J, Müller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P.
Gut; 2005 Dec 15; 54(12):1707-13. PubMed ID: 16020489
[Abstract] [Full Text] [Related]
13. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P.
J Gastroenterol Hepatol; 2007 Aug 15; 22(8):1183-9. PubMed ID: 17688659
[Abstract] [Full Text] [Related]
14. Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies.
Quigley EM, Wald A, Fidelholtz J, Boivin M, Pecher E, Earnest D.
Clin Gastroenterol Hepatol; 2006 May 15; 4(5):605-13. PubMed ID: 16678076
[Abstract] [Full Text] [Related]
15. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
Müller-Lissner S, Holtmann G, Rueegg P, Weidinger G, Löffler H.
Aliment Pharmacol Ther; 2005 Jan 01; 21(1):11-20. PubMed ID: 15644040
[Abstract] [Full Text] [Related]
16. Treatment of functional constipation with the Yun-chang capsule: a double-blind, randomized, placebo-controlled, dose-escalation trial.
Jia G, Meng MB, Huang ZW, Qing X, Lei W, Yang XN, Liu SS, Diao JC, Hu SY, Lin BH, Zhang RM.
J Gastroenterol Hepatol; 2010 Mar 01; 25(3):487-93. PubMed ID: 20370727
[Abstract] [Full Text] [Related]
17. Efficacy of linaclotide for patients with chronic constipation.
Lembo AJ, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Johnston JM.
Gastroenterology; 2010 Mar 01; 138(3):886-95.e1. PubMed ID: 20045700
[Abstract] [Full Text] [Related]
18. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation.
Mueller-Lissner S, Kamm MA, Wald A, Hinkel U, Koehler U, Richter E, Bubeck J.
Am J Gastroenterol; 2010 Apr 01; 105(4):897-903. PubMed ID: 20179697
[Abstract] [Full Text] [Related]
19. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.
Quigley EM, Vandeplassche L, Kerstens R, Ausma J.
Aliment Pharmacol Ther; 2009 Feb 01; 29(3):315-28. PubMed ID: 19035970
[Abstract] [Full Text] [Related]
20. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity.
Rodriguez-Stanley S, Zubaidi S, Proskin HM, Kralstein JR, Shetzline MA, Miner PB.
Clin Gastroenterol Hepatol; 2006 Apr 01; 4(4):442-50. PubMed ID: 16616348
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
